Brahmer JR - Search Results

1

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Topalian SL, et al. Among authors: brahmer jr. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2. N Engl J Med. 2012. PMID: 22658127 Free PMC article. Clinical Trial.

2

Adjuvant treatment in non-small cell lung cancer: Where are we now?

Juergens RA, Brahmer JR. Juergens RA, et al. Among authors: brahmer jr. J Natl Compr Canc Netw. 2006 Jul;4(6):595-600. doi: 10.6004/jnccn.2006.0049. J Natl Compr Canc Netw. 2006. PMID: 16813727 Review.

3

Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.

Juergens R, Brahmer J, Ettinger D. Juergens R, et al. Cancer Chemother Pharmacol. 2007 Apr;59(5):621-9. doi: 10.1007/s00280-006-0304-8. Epub 2006 Aug 26. Cancer Chemother Pharmacol. 2007. PMID: 16937106 Clinical Trial.

4

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Carducci MA, et al. Among authors: brahmer jr. J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.

5

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Sandler A, et al. N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884. N Engl J Med. 2006. PMID: 17167137 Free article. Clinical Trial.

6

Second-line Therapy for advanced non-small-cell lung cancer.

Hann CL, Brahmer JR. Hann CL, et al. Among authors: brahmer jr. Curr Oncol Rep. 2006 Jul;8(4):243-7. doi: 10.1007/s11912-006-0027-3. Curr Oncol Rep. 2006. PMID: 17254522 Review.

7

Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?

Juergens R, Brahmer J. Juergens R, et al. Curr Oncol Rep. 2007 Jul;9(4):255-64. doi: 10.1007/s11912-007-0031-2. Curr Oncol Rep. 2007. PMID: 17588349 Review.

8

"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".

Hann CL, Brahmer JR. Hann CL, et al. Among authors: brahmer jr. Curr Treat Options Oncol. 2007 Feb;8(1):28-37. doi: 10.1007/s11864-007-0024-2. Curr Treat Options Oncol. 2007. PMID: 17634830 Review.

9

Chemotherapy for advanced stage non-small cell lung cancer.

Fathi AT, Brahmer JR. Fathi AT, et al. Among authors: brahmer jr. Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):210-6. doi: 10.1053/j.semtcvs.2008.09.002. Semin Thorac Cardiovasc Surg. 2008. PMID: 19038730 Review.

10

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Von Hoff DD, et al. Among authors: brahmer jr. N Engl J Med. 2009 Sep 17;361(12):1164-72. doi: 10.1056/NEJMoa0905360. Epub 2009 Sep 2. N Engl J Med. 2009. PMID: 19726763 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters